-
1دورية أكاديمية
المؤلفون: Santoro, Roberto, Goglia, MartaAff1, Aff2, IDs1330402401829z_cor2, Brighi, Manuela, Curci, Fabio Pio, Amodio, Pietro Maria, Giannotti, Domenico, Goglia, Angelo, Mazzetti, Jacopo, Antolino, Laura, Bovino, Antonio, Zampaletta, Costantino, Levi Sandri, Giovanni Battista, Ruggeri, Enzo Maria
المصدر: Updates in Surgery. 76(3):963-974
-
2
المؤلفون: Kinos, Sampsa, Hagman, Helga, Halonen, Päivi, Soveri, Leena-Maija, O'Reilly, Mary, Pfeiffer, Per, Frödin, Jan-Erik, Sorbye, Halfdan, Heervä, Eetu, Liposits, Gabor, Kallio, Raija, Ålgars, Annika, Ristamäki, Raija, Salminen, Tapio, Bärlund, Maarit, Shah, Carl-Henrik, Mcdermott, Ray, Röckert, Rebecka, Flygare, Petra, Kwakman, Johannes, Teske, Arco, Punt, Cornelis, Glimelius, Bengt, Österlund, Pia
المصدر: Acta Oncologica. 63:248-258
مصطلحات موضوعية: Metastatic colorectal cancer, fluoropyrimidines, S-1, cardiotoxicity, capecitabine, 5-fluorouracil, metastasectomy
الوصف: Background and purpose: The CardioSwitch-study demonstrated that patients with solid tumors who develop cardiotoxicity on capecitabine or 5-fluorouracil (5-FU) treatment can be safely switched to S-1, an alternative fluoropyrimidine (FP). In light of the European Medicines Agency approval of S-1 in metastatic colorectal cancer (mCRC), this analysis provides more detailed safety and efficacy information, and data regarding metastasectomy and/or local ablative therapy (LAT), on the mCRC patients from the original study.Materials and methods: This retrospective cohort study was conducted at 12 European centers. The primary endpoint was recurrence of cardiotoxicity after switch. For this analysis, safety data are reported for 78 mCRC patients from the CardioSwitch cohort (N = 200). Detailed efficacy and outcomes data were available for 66 mCRC patients.Results: Data for the safety of S-1 in mCRC patients were similar to the original CardioSwitch cohort and that expected for FP-based treatment, with no new concerns. Recurrent cardiotoxicity (all grade 1) with S-1-based treatment occurred in 4/78 (5%) mCRC patients; all were able to complete FP treatment. Median progression-free survival from initiation of S-1-based treatment was 9.0 months and median overall survival 26.7 months. Metastasectomy and/or LAT was performed in 33/66 (50%) patients, and S-1 was successfully used in recommended neoadjuvant/conversion or adjuvant-like combination regimens and schedules as for standard FPs.Interpretation: S-1 is a safe and effective FP alternative when mCRC patients are forced to discontinue 5-FU or capecitabine due to cardiotoxicity and can be safely used in the standard recommended regimens, settings, and schedules.
وصف الملف: electronic
-
3
المؤلفون: Westerberg, Marcus, 1990, Holmberg, Lars, Ekbom, Anders, Metcalfe, Chris, Steele, Robert, Forsberg, Anna
المصدر: Scandinavian Journal of Gastroenterology. 59(4):503-511
مصطلحات موضوعية: Colonoscopy, colorectal cancer, screening, gastroenterology, cancer
الوصف: BackgroundFewer adenomas are detected at colonoscopy in women compared to men and failure to detect adenomas and sessile serrated polyps is associated with an increased risk of post-colonoscopy colorectal cancer. The aim of this study was to investigate whether this was in part due to the greater difficulty of conducting colonoscopy in women, with the difference being more apparent in colonoscopies conducted by less skilled endoscopists.Material and methodsCross-sectional exploratory analysis of data on 16,551 individuals undergoing a primary colonoscopy (PCOL group) or colonoscopy after positive faecal immunochemical test (FIT group) within the randomized controlled trial SCREESCO. Endoscopist adenoma detection rate (ADR; low or high) was determined based on each endoscopist's colonoscopies performed in SCREESCO. In each study group, the relationship between the sex difference in colonoscopy outcome and endoscopist ADR was assessed using multiplicative interaction tests.ResultsEndoscopists performed equally many colonoscopies in men and women (median 52% men). There were no signs of effect modification of the risk ratio of any finding (men vs women) by endoscopist ADR in the PCOL group (p = 0.33) or the FIT group (p = 0.30). The proportion of incomplete index colonoscopies was lower in men than in women in both groups and there was no effect modification by endoscopist ADR in either the PCOL group (p = 0.41) or the FIT group (p = 0.96).ConclusionsThis study provides no evidence that endoscopist skill measured by ADR underlies the sex difference in adenoma detection at colonoscopy. This study has trial number NCT02078804 and is registered with ClinicalTrials.gov.
وصف الملف: electronic
-
4
المؤلفون: Gkekas, Ioannis, 1981, Novotny, Jan, Kaprio, Tuomas, Beilmann-Lehtonen, Ines, Fabian, Pavel, Tavelin, Björn, Böckelman, Camilla, Edin, Sofia, Strigård, Karin, Svoboda, Tomas, Hagström, Jaana, Barsova, Lucie, Jirasek, Tomas, Haglund, Caj, Palmqvist, Richard, Gunnarsson, Ulf
المصدر: Journal of Surgical Oncology. 129(7):1295-1304
مصطلحات موضوعية: colorectal cancer, non-colorectal malignancy, sporadic deficient mismatch repair
الوصف: Background and Objectives: Disparities between tumors arising via different sporadic carcinogenetic pathways have not been studied systematically. This retrospective multicenter cohort study evaluated the differences in the risk for non-colorectal malignancy between sporadic colorectal cancer (CRC) patients from different DNA mismatch repair status.Methods: A retrospective European multicenter cohort study including in total of 1706 CRC patients treated between 1996 and 2019 in three different countries. The proficiency (pMMR) or deficiency (dMMR) of mismatch repair was determined by immunohistochemistry. Cases were analyzed for tumor BRAFV600E mutation, and BRAF mutated tumors were further analyzed for hypermethylation status in the promoter region of MLH1 to distinguish between sporadic and hereditary cases. Swedish and Finish patients were matched with their respective National Cancer Registries. For the Czech cohort, thorough scrutiny of medical files was performed to identify any non-colorectal malignancy within 20 years before or after the diagnosis of CRC. Poisson regression analysis was performed to identify the incidence rates of non-colorectal malignancies. For validation purposes, standardized incidence ratios were calculated for the Swedish cases adjusted for age, year, and sex.Results: Of the 1706 CRC patients included in the analysis, 819 were female [48%], median age at surgery was 67 years [interquartile range: 60–75], and sporadic dMMR was found in 188 patients (11%). Patients with sporadic dMMR CRC had a higher incidence rate ratio (IRR) for non-colorectal malignancy before and after diagnosis compared to patients with a pMMR tumor, in both uni- (IRR = 2.49, 95% confidence interval [CI] = 1.89–3.31, p = 0.003) and multivariable analysis (IRR = 2.24, 95% CI = 1.67–3.01, p = 0.004). This association applied whether or not the non-colorectal tumor developed before or after the diagnosis of CRC in both uni- (IRR = 1.91, 95% CI = 1.28–2.98, p = 0.004), (IRR = 2.45, 95% CI = 1.72–3.49, p = 0.004) and multivariable analysis (IRR = 1.67,95% CI = 1.05–2.65, p = 0.029), (IRR = 2.35, 95% CI = 1.63–3.42, p = 0.005), respectively.Conclusion: In this retrospective European multicenter cohort study, patients with sporadic dMMR CRC had a higher risk for non-colorectal malignancy than those with pMMR CRC. These findings indicate the need for further studies to establish the need for and design of surveillance strategies for patients with dMMR CRC.
وصف الملف: electronic
-
5
المؤلفون: Pham, Thu Thi, Nimptsch, Katharina, Aleksandrova, Krasimira, Jenab, Mazda, Fedirko, Veronika, Wu, Kana, Eriksen, Anne Kirstine, Tjønneland, Anne, Severi, Gianluca, Rothwell, Joseph, Kaaks, Rudolf, Katzke, Verena, Catalano, Alberto, Agnoli, Claudia, Masala, Giovanna, De Magistris, Maria Santucci, Tumino, Rosario, Vermeulen, Roel, Aizpurua, Amaia, Trobajo-Sanmartín, Camino, Chirlaque, María-Dolores, Sánchez, Maria-Jose, Lu, Sai San Moon, Cross, Amanda J., Christakoudi, Sofia, Weiderpass, Elisabete, Pischon, Tobias
المصدر: International Journal of Cancer. 154(9):1596-1606
مصطلحات موضوعية: colorectal cancer, EPIC, mortality, pre-diagnostic, resistin, survival
الوصف: Resistin is a protein involved in inflammation and angiogenesis processes and may play a role in the progression of colorectal cancer (CRC). However, it remains unclear whether resistin is associated with increased mortality after CRC diagnosis. We examined pre-diagnostic serum resistin concentrations in relation to CRC-specific and all-cause mortality among 1343 incident CRC cases from the European Prospective Investigation into Cancer and Nutrition cohort. For CRC-specific mortality as the primary outcome, hazard ratios (HRs) and 95% confidence intervals (95% CI) were estimated from competing risk analyses based on cause-specific Cox proportional hazards models and further in sensitivity analyses using Fine–Gray proportional subdistribution hazards models. For all-cause mortality as the secondary outcome, Cox proportional hazards models were used. Subgroup analyses were performed by sex, tumor subsite, tumor stage, body mass index and time to CRC diagnosis. Resistin was measured on a median of 4.8 years before CRC diagnosis. During a median follow-up of 8.2 years, 474 deaths from CRC and 147 deaths from other causes were observed. Resistin concentrations were not associated with CRC-specific mortality (HRQ4vsQ1 = 0.95, 95% CI: 0.73–1.23; Ptrend =.97; and HRper doubling of resistin concentration = 1.00; 95% CI: 0.84–1.19; P =.98) or all-cause mortality. Results from competing risk (sensitivity) analysis were similar. No associations were found in any subgroup analyses. These findings suggest no association between pre-diagnostic circulating resistin concentrations and CRC-specific or all-cause mortality among persons with CRC, and the potential insignificance of resistin in CRC progression.
وصف الملف: electronic
-
6
المؤلفون: Sakari, Thorbjörn, Sköldberg, Filip, Dietrich, Caroline E., Nordenvall, Caroline, Karlbom, Urban
المصدر: Colorectal Disease. 26(2):300-308
مصطلحات موضوعية: colorectal cancer, emergency surgery, SBO, small bowel obstruction, Surgery, Kirurgi
الوصف: AimPopulation-based data on incidence and risk factors of adhesive small bowel obstruction (SBO) are limited. The aims of this study were to assess the risk of SBO and SBO surgery after bowel resection for colorectal cancer (CRC) and to assess whether this risk is modified by minimally invasive surgery (MIS) and radiotherapy in a retrospective national study.MethodsCRCBaSe, a nationwide register linkage originating from the Swedish Colorectal Cancer Register, was used to identify Stage I–III CRC patients who underwent resection in 2007–2016, with follow-up throughout 2017. Matched CRC-free comparators (1:6) were included as a reference of SBO and SBO surgery incidence. The association between MIS and preoperative radiotherapy and the incidence rate of SBO was evaluated in adjusted multivariable Cox regression models.ResultsAmong 33 632 CRC patients and 198 649 comparators, the 5-year cumulative incidence of SBO and SBO surgery was 7.6% and 2.2% among patients and 0.6% and 0.2% among comparators, with death as a competing risk. In all patients, MIS was associated with a reduced incidence of SBO (hazard ratio [HR] 0.7, 95% CI 0.6–0.8) and SBO surgery (HR 0.5, 95% CI 0.3–0.7). In rectal cancer patients, radiotherapy was associated with an increased incidence of SBO (HR 1.6, 95% CI 1.4–1.8) and SBO surgery (HR 1.7, 95% CI 1.3–2.3).DiscussionColorectal cancer surgery is associated with a marked increase in risk of SBO, compared with the general population. The incidence is further increased if open surgery or radiotherapy is performed.
وصف الملف: electronic
-
7دورية أكاديمية
المؤلفون: Chen, Jun-he, Wei, Cheng-ming, Lin, Qian-yu, Wang, Zi, Zhang, Fu-ming, Shi, Mei-na, Lan, Wen-jian, Sun, Chang-gang, Lin, Wan-jun, Ma, Wen-zheAff1, IDs1159602428831_cor10
المصدر: Current Medical Science. :1-8
-
8دورية أكاديمية
المؤلفون: Yu, LongAff1, Aff2, Wang, Hao, Wang, Fulong, Guo, Jian, Xiao, Binyi, Hou, Zhenlin, Lu, Zhenhai, Pan, Zhizhong, Zhou, Yaxian, Ye, Sibin, Wan, Desen, Lin, BoAff3, IDs12094024035666_cor12, Ou, QingjianAff1, Aff2, IDs12094024035666_cor13, Fang, YujingAff1, Aff2, IDs12094024035666_cor14
المصدر: Clinical and Translational Oncology. :1-14
-
9دورية أكاديمية
المؤلفون: Aghalari, Motahareh, Bizaki, Hossein KhaleghiAff1, IDs1104202419703w_cor2
المصدر: Multimedia Tools and Applications: An International Journal. :1-26
-
10دورية أكاديمية
المؤلفون: Hille, GeorgAff1, Aff2, IDs11548024032179_cor1, Tummala, Pavan, Spitz, Lena, Saalfeld, SylviaAff2, Aff3
المصدر: International Journal of Computer Assisted Radiology and Surgery: A journal for interdisciplinary research, development and applications of image guided diagnosis and therapy. :1-9
إعادة تعيين المنقحات
عرض المنقحات (%%عد%%)
Full Text Finder 
PDF full text from Publisher